The cancer immunotherapy developer's latest round included pharmaceutical producers and co-founders Juno Therapeutics and WuXi AppTec.

The CNS disorder drug developer has launched with $76m from investors including Biogen, Bristol Myers Squibb and Pfizer Ventures.

GV co-led a series C round for the healthcare collaboration service together with F-Prime Capital, Andreessen Horowitz and Transformation Capital, taking its overall funding past $101m.

Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC have returned for the series C-1 round having backed the U-M spinout's series C last year.

Genscript Biotech's multiple myeloma-focused spinoff, which counts Eli Lilly and Johnson & Johnson among its investors, has completed an initial public offering in the US.

Eli Lilly will collaborate on five drug candidates based on the Oxford and Karolinska Institute spinout's exosome delivery technology.

Existing backer GV returned to take part in a $100m round for the clinical data software provider that also attracted new investor Regeneron Pharmaceuticals.

Johnson & Johnson and Varian Medical Systems are in line for exits after cancer therapy developer Fusion filed for a $100m initial public offering.